SCHEMBL6935023

SCHEMBL6935023

Cc1cccc(-c2c(-c3ccncc3)nc(NCCC(N)c3ccccc3F)n(C)c2=O)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 4/20 0.63
MAPK9 P45984 3/20 0.63
MAP4K4 O95819 2/20 0.63
CDC42BPA Q5VT25 2/20 0.63
MINK1 Q8N4C8 2/20 0.63
FRK P42685 1/20 0.63
CSNK1A1 P48729 1/20 0.63
MAP4K5 Q9Y4K4 1/20 0.63
MAPK14 Q16539 4/20 0.49
MAPK13 O15264 2/20 0.49
EGFR P00533 1/20 0.49
ERBB2 P04626 1/20 0.49
LYN P07948 1/20 0.49
PRKACA P17612 1/20 0.49
PRKCI P41743 1/20 0.49
MAPK8 P45983 1/20 0.49
MAPK12 P53778 1/20 0.49
MAPK10 P53779 1/20 0.49
MAP3K10 Q02779 1/20 0.49
PRKCZ Q05513 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8324819 0.95 CSNK1D (0.58) CSNK1DMAPK9MAP4K4CDC42BPAMINK1
SCHEMBL6931295 0.90 MAPK9 (0.63) CSNK1DMAPK9MAP4K4CDC42BPAMINK1
SCHEMBL6934560 0.90 MAPK9 (0.51) CSNK1DMAPK9MAP4K4CDC42BPAMINK1
SCHEMBL6937920 0.88 MAPK9 (0.70) CSNK1DMAPK9MAP4K4CDC42BPAMINK1
SCHEMBL6934694 0.88 MAPK14 (0.50) CSNK1DMAPK9MAP4K4CDC42BPAMINK1
SCHEMBL7458856 0.86 MAPK14 (0.47) CSNK1DMAPK9MAP4K4CDC42BPAMINK1
SCHEMBL6932114 0.83 MAPK9 (0.53) CSNK1DMAPK9MAP4K4CDC42BPAMINK1
SCHEMBL6937312 0.82 MAPK14 (0.49) CSNK1DMAPK9MAP4K4CDC42BPAMINK1
Hydrochloric Acid SCHEMBL6931870 0.81 MAPK14 (0.49) CSNK1DMAPK9MAP4K4CDC42BPAMINK1
SCHEMBL8466247 0.80 MAPK9 (0.51) CSNK1DMAPK9MAP4K4CDC42BPAMINK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073704-A1 Substituted pyridone compounds and methods of use AMGEN INC. 2003-04-17 US claimed
US-6096753-A Substituted pyrimidinone and pyridone compounds and methods of use AMGEN INC. (US) 2000-08-01 US claimed
EP-0948496-A2 SUBSTITUTED PYRIMIDINONE AND PYRIDONE COMPOUNDS AND METHODS OF USE Amgen inc. (US) 1999-10-13 EP claimed
WO-1998024780-A2 SUBSTITUTED PYRIMIDINONE AND PYRIDINONE COMPOUNDS AND THEIR USE AMGEN INC. (US) 1998-06-11 WO claimed
US-6649604-B2 Analgesics; antidiabetic agents; antiinflamamtory agents AMGEN INC. 2003-11-18 US disclosed
US-20030073704-A1 Substituted pyridone compounds and methods of use AMGEN INC. 2003-04-17 US disclosed
US-6420385-B1 INFLAMMATORY, PAIN AND DIABETES DISEASES, AMGEN INC. 2002-07-16 US disclosed
US-6096753-A Substituted pyrimidinone and pyridone compounds and methods of use AMGEN INC. (US) 2000-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073704-A1 Substituted pyridone compounds and methods of use IL6, IL1B, IL1A CSNK1D 1761/4885MAPK9 1247/4885MAP4K4 761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.